6,719 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Accredited Wealth Management LLC

Accredited Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,719 shares of the biopharmaceutical company’s stock, valued at approximately $621,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC increased its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock worth $3,293,822,000 after acquiring an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after acquiring an additional 749,047 shares in the last quarter. Norges Bank bought a new position in Gilead Sciences in the 4th quarter worth about $1,789,254,000. Finally, Northern Trust Corp grew its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, Royal Bank of Canada lifted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 160,605 shares of company stock valued at $16,718,136 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.4 %

Shares of NASDAQ:GILD opened at $103.68 on Friday. The stock has a 50 day moving average of $108.69 and a 200 day moving average of $98.82. The company has a market cap of $129.10 billion, a PE ratio of 280.22, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.32) earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.